Corresponding Author: Kao-Ping Chua, MD, PhD, Department of Pediatrics, University of Michigan, 300 N Ingalls St, SPC 5456, Rm 6E18, Ann Arbor, MI 48109-5456 (chuak@med.umich.edu).
Published Online: August 17, 2020. doi:10.1001/jamainternmed.2020.2759
Conflict of Interest Disclosures: None reported.
Funding/Support: Dr Chua is supported by a career development award from the National Institute on Drug Abuse (grant number 1K08DA048110-01). Dr Conti is supported by a grant from the American Cancer Society.
Role of the Funder/Sponsor: The funders had no role in the creation of this article; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
1.Lupkin
S. FDA Grants Experimental Coronavirus Drug Benefits for Rare Disease Treatments. National Public Radio. March 24, 2020.
5.Chua
KP , Conti
RM . Revocation of Orphan Drug Designation for Extended-Release Buprenorphine Injection: Implications and Next Steps. Health Affairs Blog. March 5, 2020.
8.Bagley
N , Berger
M , Chandra
A , Garthwaite
C , Stern
A . The orphan drug act at 30. In: Lerner
J , Stern
S , eds. Innovation Policy and the Economy, 2018, Volume 19 (National Bureau of Economic Research Innovation Policy and the Economy). Chicago, IL: University of Chicago Press; 2019.